Related Experiment Video

Updated: Jul 7, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Small artery remodelling in hypertension: causes, consequences and therapeutic implications

Michael J Mulvany1

  • 1Department of Pharmacology, University of Aarhus, University Park 240, 8000 Aarhus C, Denmark. mm@farm.au.dk

Medical & Biological Engineering & Computing
|January 30, 2008
PubMed

Insights

Essential hypertension treatment should target abnormal blood vessel structure. Therapies reducing peripheral resistance can normalize vascular changes and improve patient outcomes beyond just lowering blood pressure.

Area of Science:

  • Cardiovascular Medicine
  • Hypertension Research
  • Vascular Biology

Background:

  • Essential hypertension management primarily focuses on blood pressure reduction, often neglecting underlying pathological changes in peripheral resistance and cardiovascular structure.
  • Altered resistance vessel structure, characterized by an increased media:lumen ratio due to inward eutrophic remodeling, is a key pathological feature.

Purpose of the Study:

  • To review the evidence for normalizing resistance vessel structure as a therapeutic target in hypertension.
  • To explore the potential of antihypertensive therapies to rectify abnormal vascular structure and improve prognosis.

Main Methods:

  • Literature review synthesizing evidence on resistance vasculature structure, therapeutic interventions, prognostic implications, and cellular mechanisms.
  • Analysis of studies investigating the effects of vasodilatation and vasoconstriction on vascular remodeling.

Main Results:

  • Evidence indicates that essential hypertension involves inward eutrophic remodeling of resistance vessels, increasing the media:lumen ratio.
  • Therapies promoting vasodilatation show potential in rectifying abnormal vascular structure.
  • Altered small artery structure is linked to adverse prognostic consequences in hypertensive patients.

Conclusions:

  • Reducing peripheral resistance through antihypertensive therapy can improve abnormal vascular structure, in addition to lowering blood pressure.
  • Vasodilator therapies may offer a strategy to normalize vascular remodeling and enhance treatment outcomes in hypertension.
  • Targeting vascular structure alongside blood pressure may be crucial for improving the long-term prognosis of essential hypertension.

More Related Videos

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...